Physician profile
Ravi Gupta
NPI 1922077338
$5,489.51
in general payments reported to CMS, 2019-2025
49 companies · $803 in 2025
The $803 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $769 · 2021: $790 · 2022: $704 · 2023: $741 · 2024: $772 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $716.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $624.84 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $485.70 | 2019-2025 | |
| Novo Nordisk INC | $406.25 | 2019-2025 | Ozempic |
| Abbott Laboratories | $328.54 | 2020-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $302.41 | 2021-2025 | Verquvo, Capvaxive, Keytruda |
| Novartis Pharmaceuticals Corporation | $252.22 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $215.91 | 2019-2022 | |
| Amgen INC. | $211.06 | 2019-2024 | Repatha, Otezla |
| Boston Scientific Corporation | $179.48 | 2024-2025 | Watchman Flx, General - Pain Management |
| Lilly USA, LLC | $170.53 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.15 | 2019-2025 | Xifaxan, Trulance |
| Heartflow, INC. | $124.72 | 2024 | |
| Pfizer INC. | $122.61 | 2020-2025 | |
| Astellas Pharma US INC | $117.67 | 2019-2024 | Veozah |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.